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Summary 
Chronic viral infections and malignant tumors induce T-cells with a reduced ability to secrete 
effector cytokines and up-regulated PD-1 expression. These patterns have so far been 
considered to mark terminally differentiated “exhausted” T-cells. Several clinical and recent 
experimental observations, however, indicate that phenotypically “exhausted” T-cells still 
mediate a critical level of pathogen or tumor control. We are therefore reviewing evidence 
indicating that the exhausted phenotype results from a differentiation process in which T-cells 
stably adjust their effector capacity to the needs of chronic infection. We argue that this 
phenotype is optimized to cause minimal tissue damage while still mediating a critical level of 
pathogen control. In contrast to the presently held view of functional exhaustion, this new 
concept reflects better the pathophysiology and clinical manifestations of persisting infections 
and it provides a rational for emerging therapies that enhance T-cell activity in chronic infection 
and cancer by blocking inhibitory receptors. 
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Main Text 
1. Introduction 
Most pathogens are rapidly cleared and the immune system becomes only transiently exposed 
to foreign antigens and inflammation. Such acute infections trigger the generation of large 
numbers of short-lived effector T-cells and the formation of memory T-cells1-8. Following such 
infections, T-cells typically co-express multiple cytokines (TNF, IFN IL-2) and cytotoxic effector 
molecules - a phenotype often referred to as polyfunctional9. A different outcome arises when 
infections become chronic and when viruses persist at high levels over long periods as in 
Human-Immunodeficiency-Virus (HIV) or Human-Hepatitis-C Virus (HCV) infections. Such 
conditions induce T-cells lacking the typical polyfunctional phenotype and T-cells retain the 
expression of inhibitory receptors including PD-1, Lag-3, Tim-3, and CD1609-17. Very similar 
phenotypes can be observed, when T-cells are long-term exposed to tumor-antigen18-20. The 
prevailing view is that this phenotype marks functionally severely impaired so called “exhausted 
T-cells”, that conventional memory T-cells are not being formed in persisting infections21, and 
that chronic infections cause a progressively weakening response and a shutdown of T-cell 
mediated immunity.  
However, several clinical observations and far reaching experimental evidence, including the 
therapeutic effects achieved by blocking PD-1 signaling, are difficult to align with the concept 
that the T-cell response only progressively deteriorates in chronic infections. Moreover, the term 
“exhausted T-cells” implies that T-cells acquire a non-functional status. However, we question 
whether the multifaceted expression pattern of receptors that inhibit T-cell function have solely 
evolved to render T-cells non-functional. Such an outcome could be achieved by simply deleting 
antigen-specific T-cells.  
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To resolve these discrepancies, we are proposing a significant revision of the current concept of 
T-cell responses in chronic infections. Following the idea that chronic infections require an 
equilibrium between control of viral replication and the level of immune-mediated pathology 
caused by the persisting T-cell responses22, we argue and provide evidence that functional 
adaptation, specialization, and the acquisition of stable phenotypes, rather than exhaustion, are 
the driving forces that determine T-cell response in chronic infections. Thus, we posit that the 
phenotype of exhausted T-cells actually reflects a finely tuned effector population that is 
optimized to fulfill a certain level of effector function and pathogen control without causing 
overwhelming immunopathology.  
2. Origin of the T-cell exhaustion concept 
The idea that chronic infections exhaust the T-cell response was originally formulated following 
studies in mice persistently infected with the Lymphocytic choriomeningitis virus (LCMV) docile 
strain. In these mice, the possibility to in vitro expand antigen-specific T-cells declines over time 
which led to the conclusion that a continuing infection “exhausts” or severely diminishes the 
pathogen-specific T-cell response13. The introduction of the tetramer technology and transgenic 
CD8 T-cells specific for an LCMV-derived antigen (P14) enabled more detailed 
characterizations and proved a substantial loss of effector T-cells. Nonetheless, depending on 
the pathogen dose and the epitope being studied, a significant fraction of T-cells bypasses 
deletion. This applies in LCMV clone-13 infections to T-cells specific for the gp33 peptide while 
their np396-specific counterparts become deleted12,14. The latter is thought to result from a 
higher avidity of T-cells for the np396 than for the gp33 peptide23. Moreover, the availability of 
LCMV strains which differ in their in vivo persistence (i.e. acute WE or Armstrong and chronic 
clone-13 or docile strains) facilitated in depth characterizations of how the duration of infections 
caused by very similar pathogens impacts T-cell differentiation. These studies prompted the 
discovery of the abovementioned chronic infection phenotype15,24 and established that acquiring 
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this phenotype and deletion of antigen-specific T-cells are in parallel or sequentially occurring 
events. Taking into count that T-cells which do not become deleted show a different phenotype, 
that they are difficult to re-expand in vitro, and that they do not survive well following adoptive 
transfer into antigen negative hosts25 all this sustained the concept that the residual T-cells are 
non-functional - a notion that intuitively goes along with the inability of the immune-system to 
clear the virus. Alongside, the use of the term “T-cell exhaustion” significantly evolved - from 
referring to the elimination of antigen-specific T-cells to now being predominantly used to refer 
to T-cells which bear the chronic infection phenotype. While antigen-specific T-cells in persisting 
infections clearly differ from their counterparts found in acute infections, we focus our review on 
aspects highlighting that these retained T-cells are not an inert non-functional population and we 
favor the view that these retained T-cells fulfill special functions. We are thereby also resolving 
the confusion that we refer to these T-cells as being exhausted despite the strong evidence that 
we can re-activate their effector potential for instance by blocking PD-1 signaling.  
3. Evidence that functional T-cells are maintained in chronic infections and tumors 
A characteristic feature of many persisting infections, including HIV, SIV [Simian 
Immunodeficiency Virus] or HCV infections, is the appearance of virus variants expressing 
mutated T-cell epitopes. This phenomenon clearly requires ongoing antigen-specific CD8+ T-cell 
function but whether or not this selection can only be mediated by T-cells with a normal effector 
phenotype or how much T-cells with an exhausted phenotype could be involved remains 
unclear. Nonetheless, the late occurring appearance of mutant viruses in established chronic 
infection is a fundamental indicator for long-term maintenance of functional T-cell responses 
and highlights that exhausted T-cell populations possibly contribute to select escape 
variants26,27. The association between the late emergence of escape mutations, concomitant 
steep viral load increase, and disease progression to AIDS in HIV infections underline the 
aforementioned considerations. Moreover, the numbers of HIV-specific T-cells can rise following 
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an interruption of anti-retroviral therapy28,29. Along with the evidence that HIV infections impair 
the thymic output, this furthermore reveals the retention of T-cells in established chronic 
infections that can expand substantially30,31. The demonstration that virus titers strongly rise 
following depletion of CD8+ T-cells in SIV infected macaques32-34 and that protective immune 
responses can be elicited upon vaccinating SIV infected Rhesus macaques35 further underscore 
the strong effector capacity of CD8+ T-cells in established chronic infections. 
T-cells with an exhausted phenotype can also be found following chronic antigen stimulation in 
tumors19,36-38. Despite showing this phenotype, there is a clear positive correlation between 
number of CD8+ tumor infiltrating lymphocytes (TIL) and a favorable clinical prognosis39,40. 
Remarkably, 58 out of 60 studies highlight this correlation across patients with all major types of 
cancer39-41. Consistent with the aforementioned immune control in the presence of 
phenotypically exhausted T-cells, there is evidence that PD-1high CD8+ T-cells can express 
similar or even elevated levels of cytotoxic molecules compared to cells with a less pronounced 
exhausted phenotype37,42-45.  
The strongest evidence that exhausted cells retain the ability to mount a potent effector 
response comes from the many studies in which strong anti-tumor or anti-viral immunity could 
be restored by blocking PD-1/PD-L1 interaction alone or in combination with targeting other 
receptors46-52. This approach of antibody-mediated “checkpoint blockade” is now increasingly 
used to treat patients with cancer and its impact on chronic infections in humans is being 
evaluated (Box 1). The efficacy of blocking PD-1 signaling strongly implies that T-cell function in 
chronic infections and cancer is not solely attenuated because of a CD8 T-cell intrinsic loss of 
function but rather because the function of these T-cells is controlled by external regulatory 
mechanisms that involve PD-1 signaling.  
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Another point to consider is that LCMV clone-13 infections, in which many features of exhausted 
T-cells including the relevance of PD-1 expression were established15,46, show virus load 
kinetics that are most indicative for a long-term maintained effector T-cell response. Starting 
from high levels, the virus titer usually strongly declines to levels that are undetectable in the 
blood within 4-8 weeks post infection and also decreases in infected organs with the kidneys 
being a major exception as they continue to contain high titers14,54. Though the precise 
protective mechanisms underlying the decline remain unclear, this observation signals that the 
presence of an exhausted T-cell phenotype does not preclude substantial virus control. 
Infections which show a latent phase (for example Epstein-Barr-Virus [EBV] or Cytomegalovirus 
[CMV] infections) differ in many respects from the aforementioned persisting infections but they 
are similar in such that T-cells become repetitively exposed to antigen. The mostly undetectable 
pathogen loads and the occasionally occurring virus re-activation imply that T-cells are exposed 
only to low antigen levels. Nonetheless, T-cells specific for antigens derived from latently-
persisting pathogens often increase over time - a process known as memory inflation55. T-cells 
with such specificity often appear more activated than memory T-cells formed following resolved 
infections and they express KLRG-156 – a marker that is typically expressed by T-cells in the 
acute infection phase24. The latter indicates substantial antigen exposure over time and yet the 
T-cells retain a high functional capacity and strongly respond to virus re-activation57-59. Thus, 
repetitive exposure to pathogen-derived antigen does not preclude or extinct functional effector 
and memory T-cell responses. Irrespectively of the repetitive antigen exposure, T-cells specific 
for latent infections lack or express only very low levels of PD-1 indicating that PD-1 might in 
these infections signal recent activation60. The latter also suggests that stable PD-1 expression 
might strictly correlate with the strength of antigen-stimulation, which is possibly lower in latent 
than in active chronic infections. This idea would be well in line with the concept that PD-1 
serves as a rheostat following strong T-cell stimulation61. Moreover, several studies in active 
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chronic infections established links between the magnitude of T-cell stimulation (or TCR avidity) 
and T-cell fate. Accordingly, lower avidity or weaker stimulated T-cells are more prone to retain 
a normal phenotype while higher avidity T-cells acquire a chronic infection phenotype or 
become deleted62,63. This is somewhat reminiscent of the fact that T-cells retain a rather normal 
effector phenotype in latent infections in which T-cells most likely receive lower TCR stimulation 
due to a lower level of antigen-exposure.  
4. T-cells undergo stable differentiation in persisting infections and form memory-like cells  
The aforementioned examples underline that CD8+ T-cells retain at least partial control over 
virus load in chronic infections and tumors at time points, when the majority of T-cells show an 
“exhausted” phenotype. What remains unclear is how such long-term persisting T-cell 
responses are maintained, which fraction of cells remain functional and what degree of virus 
control can be mediated by T-cells in chronic infections. To address this, we recently asked 
what happens when phenotypically “exhausted” T-cell populations are removed from a chronic 
LCMV clone-13 infection and re-exposed to antigen in the context of an acute LCMV Armstrong 
infection64. Surprisingly, we observed that T-cells which homogenously expressed high levels of 
PD-1 and low levels of cytokines can undergo robust re-expansion, can form secondary effector 
T-cells, and even protected against pathogen challenge following transfer into acute infections.  
Unexpectedly, even though the transferred cells were exposed only to an acute infection, the 
vast majority of re-expanded T-cells still displayed the “exhausted” T-cell phenotype as they 
continued to express low levels of cytokines and retained PD-1 expression. Most interestingly, 
the “exhausted” phenotype was retained even when T-cells from chronic infection were 
challenged 4 weeks after they had been transferred into naïve hosts (Figure 1). This outcome 
also implies the presence of T-cells with memory-like properties among the T-cells transferred 
into the naïve hosts – a notion that will be discussed in more detail below64. This stability of the 
exhausted phenotype is supported by epigenetic studies showing that chronic LCMV clone-13 
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infections induce profound and permanent de-methylations in the PD-1 promoter region. The 
de-methylation was maintained in antigen-specific T-cells long after LCMV clone-13 virus load 
has dropped below detectable levels in the blood65. A lack of methylation in the PD-1 promoter 
region has also been observed among antigen-specific CD8 T-cells from HIV patients which 
have been treated long-term (>2 years) with anti-retroviral therapy or in elite controllers66. The 
latter further indicates a fixation of the epigenetic imprint in the PD-1 locus. The view that T-cells 
undergo a stable form of differentiation in chronic infections is also supported by studies 
showing that in spontaneously resolved HCV infection, CD8+ T-cells retain an exhausted 
phenotype even after pathogen clearance67.  
What remains unknown, however, is when T-cells undergo this differentiation. The incremental 
appearance of T-cells with an “exhausted” phenotype led to the conclusion that prolonged 
exposure to antigen and inflammation causes a progressively occurring acquisition of an 
exhausted phenotype68. Of note, this progression has only been described at the level of the 
entire population of antigen-specific T-cells but a direct demonstration that a T-cell, which at an 
early phase of a chronic infection displayed a normal phenotype, shows an exhausted 
phenotype at a later stage has not yet been performed. It also needs to be acknowledged that a 
fraction of virus-specific T-cells show already in the early phase of a LCMV clone-13 infection 
the typical mono-functional cytokine signature (low level IFN, no TNF production) and that a 
considerable number of antigen-specific T-cells display this phenotype in the early phase of 
acute infections24. This suggests that T-cells displaying a key feature of “exhaustion” might be 
constitutively generated following activation in viral infections. Thus, T-cells with a normal profile 
and T-cells with an “exhausted” phenotype might be formed in parallel in the early phase of an 
infection and, depending on whether or not the infection remains acute or becomes chronic, a 
selective outgrowth occurs over time favoring one over the other T-cell phenotype. This concept 
that the “exhausted” T-cell phenotype could be generated already at very early stages during 
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the infection and that these T-cells progressively increase - from an initially numerically 
underrepresented population to becoming a dominant  population - would also be very well in 
line with the aforementioned phenotypic stability of the “exhausted” phenotype.  
Two recent papers resolved the bulk population of antigen-specific T-cells in acute infections 
into cells that originate from the same naïve precursor (referred to as T-cell families)69,70. 
Interestingly, families of T-cells that are initially underrepresented at the population level and 
whose phenotype and cytokine secretion profiles substantially differed from the average 
phenotype of the population, showed the highest secondary re-expansion potential. Thus, a 
higher re-expansion potential of underrepresented populations or families could effectively re-
shape the global phenotype of a T-cell population following re-expansion. Such remodeling 
could also occur over time in chronic infection and this could result in a preferential outgrowth or 
selective survival of T-cells stably displaying an exhausted phenotype over T-cells that show a 
conventional phenotype and which dominate the early phase of chronic infection.  
5. Why are memory-like cells formed in chronic infections? 
The aforementioned survival of a fraction of exhausted T-cells following transfer into antigen-
free hosts, the ability of these T-cells to undergo re-expansion, and that the cells retain a 
particular phenotype are hallmark features of memory T-cells64. We therefore propose that a 
fraction of T-cells in chronic infections form cells that behave like memory cells and that pass an 
exhausted phenotype to their progeny (Figure 2). Memory T-cells formed after an acute 
infection ensure a rapid generation of large numbers of effector T-cells upon pathogen re-
exposure5,6,71. But why should cells with memory-like behavior be formed in chronic infections? 
These cells could in chronic infections constitute a reservoir to sustain the pool of effector T-
cells (Figure 2). In fact, it appears very unlikely that effector T-cells, which are formed for 
instance at the beginning of an HIV or HCV infection, may persist over months or years. More 
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likely, these effector populations are maintained through memory-like cells that constantly 
replenish a pool of otherwise short-lived effector T-cells. Such a replacement seems to occur in 
CMV infections55. A precursor progeny relation between subpopulations of T-cells that differ in 
expressing Tbox transcription factors has also been shown in LCMV clone-13 infected mice72. 
This strongly suggests that long-term effector T-cell responses in chronic infections are 
maintained by both functional diversification and cells with memory-like features.  
Interestingly, it has long ago been realized that the elimination of CD4 T-cells increases total 
virus load and decreases the number of pathogen-specific T-cells in chronic LCMV 
infections14,54. The precise mechanisms how CD4 T-cells enhance survival and effector function 
of CD8 T-cells remain unclear. We hypothesize that CD4 T-cells might fulfill in chronic infections 
a similar function in maintaining memory T-cells as following acute infections73. Accordingly, the 
deterioration in the T-cell response following CD4 depletion in chronic infection might be a 
consequence of losing these memory-like T-cells. Interestingly, a recent publication indicated 
that the impact of CD4 T-cells on CD8 T-cells in chronic infection could also be controlled by NK 
cells, which reduce the number of CD4 T-cells and concomitantly the number of CD8 T-cells74.  
We consider that memory-like T-cells comprise only a very small fraction of the population of 
antigen-specific T-cells in chronic infections. This would be well in line with the rapid and more 
than 90% decline of engrafted T-cells observed when T-cells from clone-13 infected mice were 
transferred into naïve mice in the absence of pathogen re-exposure21,25,75. We argue that this 
decline reflects only the loss of effector-like T-cells but it does not preclude the selective survival 
of a few memory-like T-cells. Besides, a decline of similar magnitude and kinetics occurs when 
day 8 effector T-cells from acute infections are transferred into naïve mice and yet a low number 
of memory T-cells survive71. Moreover, the notion that the bulk population of phenotypically 
exhausted T-cells is gene expression wise related to effector and not to memory cells does also 
not contradict our proposed model76. Instead, it rather means that specific-gene expression 
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patterns of the small sub-fraction of memory-like T-cells are most likely diluted by the numerical 
dominance of effector-like cells in the population of phenotypically exhausted T-cells.  
6. PD-1 and other inhibitory receptors enable a functional control of effector T-cells  
The goal of an immune response is to remove a pathogen. To achieve this, aggressive 
mechanisms are engaged at the risk of collateral tissue damage. We consider that the immune 
system adopts a different strategy in persisting infections that is driven by the need to balance 
pathogen control and tissue damage22. So far, the reduced ability of T-cells to produce 
cytokines in chronic infections has been seen as a sign of deteriorating T-cell function but this 
phenotype could also simply represent an effector stage that is optimized to cause less 
inflammation and immunopathology than normal effector T-cells. Such an adjustment in 
combination with persisting expression of PD-1 could be of vital importance in chronic 
infections64,65. In strong support of this concept, it was recently shown that a high dose virus 
infection, which induced a strong “exhausted” phenotype, protected mice from 
immunopathology while a lower dose, which failed to induce an “exhausted” phenotype, resulted 
in substantial pathology74,77. Similarly, disrupting the von Hippel-Lindau tumor suppressor (VHL) 
gene causes overwhelming immunopathology by enforcing cytotoxic activity of T-cells in 
persisting infections78.  
PD-1 down-modulates T-cell function in chronic infections but possibly also in acute infection as 
PD-1 is readily up-regulated following T-cell activation24. It also needs to be considered that it 
can be difficult to distinguish PD-1 expression resulting from recent stimulation versus the 
maintained expression seen in chronic infection. What remains however unclear in chronic 
infections is when and how the PD-1 pathway is utilized. The sustained virus control in chronic 
infections argues against constitutive PD-1/PD-L1 interaction. Perhaps, PD-1 and other 
inhibitory pathways are primarily acting to prevent T-cell responses in particular circumstances 
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and against tissues essential for the survival of the host. In line with this, differences in the 
expression of PD-1 and its ligands in different tissues have been described42. Moreover, a 
critical role of PD-1/PD-L1 mediated protection from endothelial damage and an otherwise 
resulting circulation failure has recently been demonstrated79. Fixing PD-1 expression in T-cells 
in chronic infection would ensure that this axis remains accessible, always ready to act as a 
potent control mechanism to limit T-cell mediated tissue damage80. Interestingly, tumor cells 
appear to benefit from this pathway and shield themselves against cytotoxic responses by 
expressing PD-1 ligands81-83.  
An important question is why blocking PD-1 in an established chronic LCMV clone-13 infection 
does not cause severe tissue damage. While this remains to be further investigated, it could be 
a question of timing but also efficacy of inhibition. Indeed, blocking PD-1/PD-L1 interaction too 
early in LCMV clone-13 infections strongly increases the severity of immunopathology79. This 
could be seen as a further indication that in late-stage chronic infections T-cells underwent 
functional specialization and cause, even when they are unleashed from PD-1/PD-L1 mediated 
inhibition, significantly less immunopathology than more aggressive early-stage effector T-cells.  
Stable PD-1 expression could also be very important to functionally control memory T-cells 
residing in tissues vulnerable to viral re-infection. The concept of tissue-resident memory CD8+ 
T-cells is now established for several types of tissues and infections84-87. Indeed, PD-1 positive 
CD8+ T-cells have been found to be preferentially retained in bone marrow, lymph nodes, 
kidney, and brain after chronic LCMV clone-13 infection42. Moreover, brain-resident effector 
memory CD8+ T-cell populations after Vesicular Stomatitis Virus infection in mice were found to 
express high levels of PD-1 and CTLA-488. At the same time, these resident T-cells often 
contain high levels of granzymes89. Thus, viral infections establish resident memory T-cell 
populations in organs repetitively targeted by similar pathogens to enable rapid pathogen 
control. The presence of PD-1 on such resident-memory cells suggests a need to safeguard the 
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cytotoxic and immunopathology causing potential of these cells by functionally controlling their 
effector function through the ligation of inhibitory receptors.  
 
7. Overall perspective 
In contrast to the idea of a sole deteriorating T-cell response in persisting infections, we argue in 
favor of the existence of a prolonged effector phase in chronic infection during which significant 
virus control is maintained by T-cells well adapted and specialized to the conditions of chronic 
infections. We consider that these T-cell responses are maintained through the formation of 
memory-like cells that stably transmit an exhausted phenotype to otherwise short-lived effector 
T-cells. In our opinion, such a prolonged effector phase reflects much better the physiology of 
chronic infections. Instead of using the term “exhausted” we therefore suggest using the term 
chronically activated effector T-cells following the proposed concept that these T-cells retain a 
certain level of effector function. Nonetheless, more detailed studies are needed to compare 
their protective capacity with that of normal effector T-cells.  
We anticipate that this prolonged effector phase only lasts for a certain period and that there is a 
final late stage at which a decline in the numbers of these chronically activated effector T-cells 
and their corresponding memory-like counterparts occurs, ultimately leading to the extinction of 
a functional T-cell response (Figure 2). The latter view is well in line with observations that T-cell 
responses in chronic HCV or HIV/SIV clearly decline when analyzed over long periods and also 
with observations indicating that even cells generated in acute infections show a decreasing 
ability to respond after going through multiple rounds of re-stimulation90,91. The length of this 
prolonged effector phase during which chronically activated effector T-cells retain considerable 
control over virus and tumor burden may vary between individuals and different types of 
infection. Presently, the major challenge is therefore to find ways to maintain T-cells in this 
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prolonged effector phase, to prevent their deterioration, and to increase their function beyond 
what can be achieved with “checkpoint blockade”.   
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Text Box 
Clinical evidence that blocking inhibitory receptors expressed on tumor- or virus-specific 
T-cells enhances anti-cancer immunity and virus control.  
Malignant diseases: 
Clinical trials in which significant clinical benefits were observed upon injecting monoclonal 
antibodies specific for inhibitory receptors (a therapy known as “checkpoint blockade”).  
 Ipilimumab (a monoclonal antibody) blocks CTLA-4 and improves disease outcome in 
patients with malignant melanoma92. This treatment has been approved by FDA and 
EMA in 2011.  
 Promising clinical results were obtained by blocking PD-1/PD-L1 interactions in patients 
with melanoma, lung and kidney cancer82,93-95. Recent data suggest that this approach 
may be more efficient and less toxic as compared to anti-CTLA-4 treatment. 
 Two phase 1 clinical trials also suggested that combined PD-1 and CTLA-4 blockade 
could further improve the clinical responses (but with increased toxicity) in melanoma 
patients95-97.  
 Currently, the reference webpage for clinical trials (www.clinicaltrials.gov) lists 320 trials 
in which inhibitory receptors are targeted for treating cancer patients (anti-CTLA-4: 216 
trials; anti-PD-1: 65 trials; anti-PD-L1: 33 trials; anti-PD-L2: 1 trial; anti-LAG-3: 2 trials; 
anti-KIR (Killer-cell Immunoglobulin-like Receptor): 3 trials) 
These trials are based on numerous research studies (reviewed in references18,98). 
 
Infectious diseases: 
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Presently, the extent to which “checkpoint blockade” improves the clinical manifestation of 
persisting infections is being evaluated. Compared to the tumor filed, much less information 
is available concerning its efficacy in chronic infections but several promising observations 
have been made some of which are listed below. Nonetheless, more clinical studies are 
needed to sustain these early observations: 
 A single dose of injecting PD-1 blocking antibody decreased viral titers in 11-15% of 
HCV patients. This included non-responders to the standard interferon therapy99.*  
 Treatment of HCV infected chimpanzees with PD-1 blocking antibodies enhanced anti-
viral T-cell responses and reduced viremia100.* 
 In-vivo manipulation of PD-1/PD-L1 interactions was shown to enhance CD8+ T-cell 
functions and extend the survival of SIV infected nonhuman primates101. 
 In vitro studies showed that the cytotoxic ability of HIV specific T-cells could be rescued 
by blocking Tim-345. 
 Recently, a melanoma patient was treated with anti-CTLA-4 mAb. Incidentally, his HCV 
infection was successfully controlled, despite that the patient did not receive anti-viral 
therapy102. 
 Currently, there are 4 ongoing trials in which anti-PD-1 or anti-PD-L1 antibodies are 
used to treat patients with chronic infectious diseases (www.clinicaltrials.gov). 
 
* These are interesting initial observations albeit the overall patient benefit observed in these 
studies remained relatively low. 
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Figure legends 
Figure 1: Assessing T-cell differentiation in acute and chronic infections 
LCMV-specific CD8+ T-cells from acutely LCMV Armstrong or chronically LCMV clone-13 
infected mice were transferred into naïve hosts. The cells were harvested from mice that had at 
least been infected 4 weeks earlier. Following the transfer, no spontaneous LCMV response 
was mounted by host CD8+ T-cells, which indicated that virus has not been transferred. 4 weeks 
after the transfer, both groups of secondary host mice were infected with an acute LCMV 
Armstrong infection. The exhausted T-cell phenotype acquired during the chronic infection 
(highlighted in red) could still be detected after the massive secondary expansion.64  
 
Figure 2: Proposed model for T-cell responses in chronic infection 
Top: In resolved infections, short-lived effector T-cells vanish shortly after pathogen clearance 
while a long-term stable memory T-cell population forms. Bottom: We propose that also in 
chronic infections a population of memory-like T-cells forms; i) which shares key features with a 
conventional memory T-cell population; ii) whose function is to constantly replace the pool of 
otherwise short-lived effector T-cells and iiI) which stably transmits the “exhausted phenotype” 
onto its decedents. This concept also suggests that the presence of a short-lived effector T-cell 
population is a shared property of acute and chronic infection with the difference that this 
population vanishes fast in acute infection while it is maintained by continuous replenishment 
over a long period (prolonged effector phase) in chronic infections. In line with clinical 
observations, we consider that this maintenance of the effector pool may eventually decline over 
time ultimately resulting in a failure to sustain the effector response.  
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